Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Mesoblast (MESO) to $24 from $15 and keeps an Overweight rating on the shares. Mesoblast is preparing to launch Ryoncil, the first-ever mesenchymal stromal cell therapy to treat pediatric steroid-refractory acute Graft vs. Host Disease, this quarter. The firm forecasts U.S. Ryoncil revenues of $24M in 2025 growing to $368M by 2032.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO: